Morphological and molecular profiles and pathways in bladder neoplasms

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 2893-2900

  Lopez Beltran, Antonio ^a   Cheng, Liang ^b   Mazzucchelli, Roberta ^c   Bianconi, Maristella ^c   Blanca, Ana ^d   Scarpelli, Marina ^c   Montironi, Rodolfo ^c,d  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Bladder neoplasm classification; Bladder neoplasms; Molecular classification; Profiling; Review

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CHROMOSOME INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INVERTED PAPILLOMA; PAPILLOMA; PRIORITY JOURNAL; PROGNOSIS; WORLD HEALTH ORGANIZATION; X CHROMOSOME;

HUMANS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 53749107225     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Mostofi FK, Sobin LH and Torlani H: Histological typing of urinary bladder tumours. In: WHO Histological Type of Tumours. Geneva, Springer, pp. 1-69, 1973.
2. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448, 1998.
3. Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Schmitz-Dräger BJ, Helpap B, Ayala AG, Tamboli P, Knowles MA, Sidransky D, Cordon-Cardo C, Jones PA, Cairns P, Simon R, Amin MB and Tyczynski JE: Infiltrating urothelial carcinoma. In: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Eble JN, Sauter G, Epstein IJ and Sesterhenn IA (eds.). Lyon, IARC press, pp. 93-109, 2004.
4. Sauter G, Algaba F, Amin MB, Busch C, Cheville J, Gasser T, Grignon DJ, Hofstadter F, Lopez-Beltran A and Epstein JI: Non-invasive urothelial tumours. In: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Eble JN, Sauter G, Epstein IJ and Sesterhenn IA (eds.). Lyon, IARC press, pp. 110-120, 2004.
5. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP and Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20, 1999.
6. Dyrskjøt L, Thykjaer T, Kruhøffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H and Orntoft TF: Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33: 90-96, 2003.
7. Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A and Cheng L: Morphological diagnosis of urothelial neoplasms. J Clin Pathol 61: 3-10, 2008.
8. Cheng L, Cheville JC, Neumann RM and Bostwick DG: Flat intraepithelial lesions of the urinary bladder. Cancer 88: 625-631, 2000.
9. Lopez-Beltran A, Cheng L, Andersson L, Brausi M, de Matteis A, Montironi R, Sesterhenn I, van del Kwast KT and Mazerolles C: Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch 440: 3-11, 2002.
10. Obermann EC, Junker K, Stoehr R, Dietmaier W, Zaak D, Schubert J, Hofstaedter F, Knuechel R and Hartmann A: Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 199: 50-57, 2003.
11. van Oers JM, Adam C, Denzinger S, Stoehr R, Bertz S, Zaak D, Stief C, Hofstaedter F, Zwarthoff EC, van der Kwast TH, Knuechel R and Hartmann A: Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 119: 1212-1215, 2006.
12. Zuk RJ, Rogers HS, Martin JE and Baithun SI: Clinicopathological importance of primary dysplasia of bladder. J Clin Pathol 41: 1277-1280, 1988.
13. Cheng L, Cheville JC, Neumann RM and Bostwick DG: Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 23: 443-447, 1999.
14. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F and Knuechel R: Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62: 809-818, 2002.
15. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP and Radvanyi F: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158: 1955-1959, 2001.
16. Mallofré C, Castillo M, Morente V and Sole M: Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 16: 187-191, 2003.
17. Cheng L, Darson M, Cheville JC, Neumann RM, Zincke H, Nehra A and Bostwick DG: Urothelial papilloma of the bladder. Clinical and biologic implications. Cancer 86: 2098-2101, 1999.
18. McKenney JK, Amin MB, and Young RH: Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol 16: 623-629, 2003.
19. van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC and van der Kwast TH: Frequent FGFR3 mutations in urothelial papilloma. J Pathol 198: 245-251, 2002.
20. Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI and Sidransky D: Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89: 514-518, 2000.
21. Lopez-Beltran A and Montironi R: Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 46: 170-176, 2004.
22. Sung MT, MacLennan GT, Lopez-Beltran A, Montironi R and Cheng L: Natural history of urothelial inverted papilloma. Cancer 107: 2622-2627, 2006.
23. Eiber M, van Oers JM, Zwarthoff EC, van der Kwast TH, Ulrich O, Helpap B, Stoerkel S, Blaszyk H, Cheville J, Sauter G, Wild PJ, Stoehr R, Hofstaedter F and Hartmann A: Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol 31: 938-496, 2007.
24. Sung MT, Eble JN, Wang M, Tan PH, Lopez-Beltran A and Cheng L: Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol 19: 1289-1294, 2006.
25. Cheng L, Neumann RM and Bostwick DG: Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer 86: 2102-2108, 1999.
26. Jones TD and Cheng L: Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol 175: 1995-2003, 2006.
27. Fujii Y, Kawakami S, Koga F, Nemoto T and Kihara K: Longterm outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 92: 559-562, 2003.
28. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P and Navone R: Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol 25: 1528-1533, 2001.
29. Barbisan F, Santinelli A, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, van der Kwast T and Montironi R: Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 112: 636-644, 2008.
30. Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX and Koch MO: Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer 101: 183-188, 2004.
31. Frigerio S, Padberg BC, Strebel RT, Lenggenhager DM, Messthaler A, Abdou MT, Moch H and Zimmermann DR: Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int J Cancer 121: 329-338, 2007.
32. Alsheikh A, Mohamedali Z, Jones E, Masterson J and Gilks CB: Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World Health Organization/International Society of Urologie Pathology. Mod Pathol 14: 267-272, 2001.
33. Montironi R, Lopez-Beltran A, Mazzucchelli R and Bostwick DG: Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol 56: 91-95, 2003.
34. Cina SJ, Lancaster-Weiss KJ, Leckseil K and Epstein JI: Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Pathol Lab Med 125: 646-651, 2001.
35. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmström PU, de la Torre M, Wester K, Allory Y, Vordos D, Caillault A, Radvanyi F, Hein AM, Jensen JL, Jensen KM, Marcussen N and Orntoft TF: Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 13: 3545-3551, 2007.
36. Herr HW: Tumor progression and survival of patients with high-grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 163: 79-80, 2000.
37. Saika T, Tsushima T, Nasu Y, Arata R, Kaku H, Kusaka N and Kumon H: Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy. Jpn J Clin Oncol 32: 461-565, 2002.
38. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK and de Medina SG: FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63: 8108-8112, 2003.
39. Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM and Orntoft TF: Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 11: 7709-7719, 2005.
40. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, Amoros A, Tardon A, Garcia-Closas R, Serra C, Carrato A, Malais N and Real FX: FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 11: 5444-5450, 2005.
41. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF and Knowles MA: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24: 5218-5225 2005.
42. Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27: 361-373, 2006.
43. Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K, von der Maase H and Orntoft TF: High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 65: 34-45, 2005.
44. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P and Waldman FM: Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11: 4044-4055, 2005.
45. Montironi R and Lopez-Beltran A: The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 13: 143-153, 2005.
46. Tomlinson DC, Baldo O, Harnden P and Knowles MA: FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213: 91-98, 2007.
47. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC and Zwarthoff EC: FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64: 1911-1914, 2004.
48. Droller MJ: Bladder cancer: State-of-the-art care. CA Cancer J Clin 48: 269-284, 1998.
49. Malmstrom PU, Buch C and Norlen BJ: Recurrence, progression, and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 21: 185-195, 1987.
50. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 49: 466-465, 2006.
51. Holmang S, Hedelin H, Anderstrom C and Johansson SL: The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153: 1823-1826, 1995.
52. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmütte C, Yang AS, Cote R, Dobeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG and Jones PA: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54: 784-78, 1994.
53. Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, Mansson W, Fioretos T and Hoglund M: Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 25: 2685-2696, 2006.
54. Harnden P: A critical appraisal of the classification of urothelial tumours: time for a review of the evidence and a radical change? BJU Int 99: 723-725, 2007.
55. Welin S, Youker J and Spratt JS Jr: The rates and patterns of growth of 375 tumors of the large intestine and rectum observed serially by Double Contrast Enema Study (Malmoe technique). Am J Roentgenol Radium Ther Nucl Med 90: 673-687, 1963.
56. Novelli MR, Williamson JA, Tomlinson IP, Elia G, Hodgson SV, Talbot IC, Bodmer WF and Wright NA: Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science 272: 1187-1190, 1996.